Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Follistatin is a secreted glycoprotein that serves as a potent endogenous antagonist of several members of the transforming growth factor-beta (TGF-beta) superfamily, most notably activin A and myostatin (GDF-8) (UniProt P19883). By binding these ligands with nearly irreversible affinity, follistatin prevents them from engaging their cognate receptors, thereby modulating diverse physiological processes including muscle growth, inflammation, and reproductive hormone secretion. In skeletal muscle, follistatin promotes hypertrophy and increases strength by neutralizing myostatin, a key negative regulator of muscle mass. This mechanism has made it a primary target for therapeutic intervention in muscle-wasting diseases such as Duchenne and Becker muscular dystrophies, as well as inclusion body myositis (NCT02726217). Beyond muscle, follistatin is involved in liver regeneration, wound healing, and the regulation of the pituitary-gonadal axis. Clinical development focuses on gene therapy delivery systems and modified protein constructs to enhance muscle mass and function while managing potential systemic effects on other TGF-beta-regulated pathways.
Follistatin acts as a high-affinity binding protein that sequesters ligands of the TGF-beta superfamily, including Activin A, Myostatin (GDF-8), and GDF-11 (UniProt P19883). By masking the receptor-binding sites of these ligands, it prevents them from activating the Activin receptor type IIA and IIB (ActRIIA/B) complex, thereby inhibiting the SMAD2/3 signaling pathway that typically restricts muscle growth and promotes fibrosis.
1 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Follistatin (FST) (FST).